New Telstra CEO Andrew Penn on Tuesday said he is considering appealing the Australian Competition and Consumer Commission’s decision last week to order a 9.4% cut in the telco’s wholesale access prices.
According to the Sydney Morning Herald, Penn said during his inaugural AGM speech that the move will wipe €51.3 million off Telstra’s EBITDA by mid-2016.
“Investors in infrastructure need…a regulatory framework where their costs are able to be recovered – otherwise investment in important infrastructure is unlikely to be made,” he said, in the report.
The ACCC on Friday ordered a one-off 9.4% reduction in Telstra’s wholesale copper access prices, even though the operator had requested permission to raise them.
Explaining its decision, the watchdog said the upward pressure on pricing – the shrinking customer base caused by the migration of consumers from Telstra’s legacy network to NBN, and fixed-mobile substitution – was more than offset by the downward pressure coming from lower expenditure and the falling cost of capital
“Users of Telstra’s network should not pay the higher costs that result from fewer customers as NBN migration occurs,” said ACCC chairman Rob Sims, in a statement on Friday.
The decision to settle on a 9.4% price cut is slightly less than the 9.6% cut the regulator proposed in June.
Full content: Herald Sun
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas